Summary. In this review, we first examine the contextual background of structure-pharmacokinetic relationships. Some concepts in drug disposition are briefly recalled, and inherent difficulties in structure-pharmacokinetic relationships are outlined. Lipophilicity is then investigated in the light of the intermolecular and intramolecular interactions it encodes. In the main body of the review, a number of pharmacokinetic processes are examined for their relations with lipophilicity. These processes are taken in a logical sequence of permeation, absorption (intestine, skin, cornea, brain), plasma protein binding, tissue distribution, volume of distribution and renal clearance. Relations between metabolism and lipophilicity are more complex, since biotransformation involves both low-energy (enzyme binding) and high-energy (catalysis) processes. Only the former may be related to lipophilicity. The conclusion argues against faulty statistics and over-interpretation.
Abbreviations: 3D-QSAR: three-dimensional QSAR; AAG: α 1 -acid glycoprotein, orosomucoid; alk: alkane; ASI: adipose storage index; BBB: blood-brain barrier; CL R : renal clearance; CNS: central nervous system; CoMFA: comparative molecular field analysis; cyc: cyclohexane; CYP: cytochrome P450; dce: 1,2-dichloroethane; f u : unbound fraction in plasma; GI: gastrointestinal; H B : total H-bonding capacity; IAM: immobilized artificial membranes; hep: heptane; K a : association constant; k cat : turnover number; K m : Michaelis constant; K s : spectral dissociation constant; log D 7.4 oct : log of octanol/water distribution coefficient at pH 7.4; log P: log of partition coefficient; MW: molecular weight; oct: octanol; PC: permeability coefficient; (Q)SARs: (quantitative) structure-activity relationships; (Q)SMRs: (quantitative) structuremetabolism relationships; (Q)SPkRs: (quantitative) structure-pharmacokinetic relationships; RP-HPLC: reversed-phase HPLC; V max : maximal velocity; V ss : volume of distribution at steady state.
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Background
Pharmacodynamic and pharmacokinetic responses
A daily challenge faced by medicinal chemists is that of uncovering and applying quantitative structure-activity relationships (QSARs). During decades, biological activity was equated almost exclusively with a pharmacodynamic response, i.e. the effects elicited in a biological system by a drug or any other xenobiotic. These effects include, among others, perturbation of membrane function, activation (agonism) or blockade (antagonism) of receptors, inhibition or induction of enzymes, binding to nucleic acids, stimulation or blockade of a functional biological response, and all manifestations of toxicity.
Progressively, a paradigm shift has taken place such that the notion of biological response has been expanded to include also the pharmacokinetic response, i.e. all effects and influences a biological system exerts on a xenobiotic [1, 2] . For many years, these effects have remained a lesser explored territory of drug design. Recently however, the new armamentarium of drug discovery (combinatorial chemistry, high-throughput screening, molecular modeling, rational drug design, etc.) has shifted the bottleneck of drug research from hit and lead discovery to lead optimization, and more specifically to pharmacokinetic lead optimization.
As a result of this evolution, medicinal chemists now find themselves trying to relate molecular structure to the various components of the pharmacokinetic response, just to discover that what the body does to a drug can be as varied and complex as what a drug does to the body:
• At the molecular level, the pharmacokinetic response includes (a) lowenergy processes such as membrane permeation, reversible binding to circulating and tissular macromolecules, and uptake by transporters, and (b) high-energy processes involving the cleavage and formation of covalent bonds, in other words biotransformation (metabolism) to form reactive or stable metabolites.
• At the organismic level, the pharmacokinetic response comprises all processes of drug disposition, namely absorption, distribution, storage, metabolism (chemical elimination) and excretion (physical elimination) [3, 4] . In this review, we focus on some of the important low-energy processes of drug disposition, giving only limited attention to biotransformation.
